Recent Census Bureau data shows a population of approximately 71 million baby boomers (the generation born from 1946-1964). What does that have to do with low vision you may ask? Approximately 40 million people worldwide have some sort of blindness, and aging increases the incidence of macular degeneration and other vision impairment that qualifies them as “low vision” persons.

Low vision is a condition of the eye in which the vision falls below 20/70 in the better seeing eye. It impairs the recipients, rendering them unable to perform daily tasks that others take for granted. With this rising aging population, the awareness of low vision therapy, diagnosis, and treatments are more widely available.

Low vision treatment can help people recover from decreased visual function due to retinal disease, brain injury, neurological damage, and other causes.

It is not only the elderly population that is affected--approximately 20% of low vision patients are children under the age...

Getting your eyes dilated can be inconvenient – dilation makes your eyes light sensitive, which can make it difficult to read books or use phones and computers for a few 4 hours.

So wouldn’t it be great to have another drop to reverse the effects of dilation?

On Dec. 31, 1990, dapiprazole, under the trade name Rev-Eyes, was approved by the FDA and thought to be the answer to all the post-dilation problems. It was marketed for treatment of medically-induced dilation by stimulating pupillary constriction and restoration of accommodative function for reading.

In clinical practice, dapiprazole took between one to two hours to return pupils to pre-dilation size.

Side effects such as stinging upon instillation, conjunctival hyperemia (redness of eye), headache, and a few instances of ptosis (lid drooping), with a possible additional dollar cost to patients, seemed to lessen dapiprazole’s overall clinical benefit.

Reading ability returned in approximately 43 minutes with...